The ever-evolving COVID-19 vaccination landscape has created many questions about who should receive additional vaccine doses, when, and why. Hear expert faculty discuss COVID-19 vaccination efficacy, the rationale for third doses and booster doses, and the data behind mixing and matching of booster doses.
Oral antiviral agents offer a new treatment option for nonhospitalized adult patients with COVID-19. Hear expert faculty discuss the safety and efficacy data of molnupiravir and nirmatrelvir (PF-07321332) plus ritonavir in outpatient adults with mild to moderate COVID-19.
Do COVID-19 treatments retain their efficacy against the SARS-CoV-2 omicron variant? Hear expert faculty discuss the use of direct-acting, small-molecule antiviral agents and monoclonal antibodies during the omicron era.
Transmissibility, disease severity, and vaccine effectiveness are different with the SARS-CoV-2 omicron variant compared with the ancestral virus and prior variants. Hear expert faculty discuss what we know about omicron.
Long COVID is a syndrome that can occur in some patients following their COVID-19 infection. Hear expert faculty discuss what is known to date about long COVID, including potential causes, risk factors, signs and symptoms, and treatment strategies under consideration.
New data have emerged regarding treatment principles and therapeutic options for nonhospitalized adult and pediatric patients with COVID-19. Hear a faculty expert describe treatment options and treatments to avoid.